Methyleugenol


Curated chemical-disease associations from CTD
Disease IDDisease nameReference
MESH:D001943 Breast Neoplasms PMID:11921183
MESH:D003328 Coronary Thrombosis PMID:16048847
MESH:D006529 Hepatomegaly PMID:23074021; PMID:23411599; PMID:26011634
MESH:D008113 Liver Neoplasms PMID:10467420; PMID:22084566; PMID:23074021; PMID:23411599; PMID:28326452; PMID:6825084
MESH:D008114 Liver Neoplasms, Experimental PMID:20004213
MESH:D008325 Mammary Neoplasms, Experimental PMID:11921183
MESH:D009336 Necrosis PMID:23411599
MESH:D009374 Neoplasms, Experimental PMID:14976343
MESH:D012376 Rodent Diseases PMID:28326452
MESH:D015431 Weight Loss PMID:26011634
MESH:D042822 Genomic Instability PMID:28326452; PMID:35690182
MESH:D056486 Chemical and Drug Induced Liver Injury PMID:26011634

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.